Report ID: 10352552 |
Published Date: 28 Apr 2025 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
Executive Summary: Acute Bacterial Skin and Skin Structure Infections Market
1. Global Demand Analysis by Region
The worldwide ABSSSI market reached USD 5.3 billion in 2024 and is expected to expand to USD 9.0 billion by 2037 with a CAGR of 5.9% during the forecast period, owing to the increased antibiotic resistance, together with more surgical procedures and better awareness of skin infections.
- North America: The market was valued at USD 3.3 billion in 2024 and is positioned to expand at a CAGR of 5.2% during the forecast period. Growth is due to MRSA affecting 42% of ABSSSI cases, combined with powerful healthcare systems and supportive reimbursement policies. The United States produces 78% of the regional revenue because treatment adoption rates remain high.
- Europe: The market was valued at USD 2.9 billion in 2024 and is positioned to expand at a 5.0% CAGR during the forecast period. Key drivers include regional healthcare demand benefits from increased government spending, where Germany (32%) and France (24%) lead in contribution. Market expansion is driven by an increase in antibiotic-resistant infections, appearing most frequently in Italy and Spain.
- Asia-Pacific (APAC): The market was valued at USD 3.5 billion in 2024 and is positioned to expand at a CAGR of 5.7% during the anticipated timeline, and account for the largest expansion rate. Major drivers include India and China expanding healthcare access at rates of 7.5% and 7.2%, respectively, alongside rapid urbanization and increasing surgical infections. Japan records the highest per capita spending at $125 per patient each year because of its aging citizenry.
- Latin America & Middle East: The LATAM market was valued at USD 1.4 billion in 2024, and the MEA market was valued at USD 0.7 billion. During the forecast timeline, the LATAM market is set to expand at a CAGR of 4.1%, and the MEA market is poised to register a CAGR of 3.5%, respectively. In LATAM, Brazil improved its healthcare system to dominate 40% of the Latin American market, meanwhile, GCC nations like the UAE and Saudi Arabia are focusing their investments on advanced medical treatments.
2. Rapidly Growing Market Segments
Market Segmentation: The acute bacterial skin and skin structure infections market research report provides comprehensive industry analysis with revenue estimates and forecasts (USD Billion) from 2025 to 2037 across the following segments:
|
Category |
Subcategory |
Key Data |
|
Drug Class |
Novel Antibiotics |
5.3% CAGR; fastest-growing segment |
|
Infection Type |
MRSA Infections |
48% of cases (U.S.), 37% (Europe); 4.7% CAGR |
|
Diabetic Foot Infections |
Escalating in India and Southeast Asia |
|
|
Route of Administration |
Oral Antibiotics |
6.1% CAGR |
|
IV Antibiotics |
62% of treatments in Germany and the U.S. |
3. Regional Market Outlook & Payer Pricing Trends
|
Region |
Government Spending |
Out-of-Pocket Costs |
Pricing/Key Trends |
|
United States |
$2.1 billion (2025) |
22% of total spending |
Branded antibiotics: $350/course (high reimbursement rates) |
|
Europe |
$1.8 billion (2025) |
12% (universal healthcare) |
Germany: $95 per capita spending (highest in Europe) |
|
Japan |
$1.2 billion (2024) |
15% |
An aging population is driving demand |
|
Australia |
$10.6 billion (2024) |
18% |
Subsidized antibiotics demand |
|
Nordic Countries |
Tax-funded system (highest public spending at $105 per capita) |
Not specified |
14% decrease in antibiotic resistance (since 2020, Sweden & Denmark stewardship programs) |
Major Drivers of the Acute Bacterial Skin & Skin Structure Infections Market
|
Category |
Key Insight |
Action/Measure |
Impact/Stats |
|
Rising Antibiotic Resistance & MRSA Infections |
42% of ABSSSI cases in the U.S. caused by MRSA infections |
FDA Fast Track Designation for antibiotics like Contepo™ |
Novel treatments required |
|
Increasing Surgical Procedures & HAIs |
11% of surgical patients acquire skin infections (2022) |
IV antibiotics reduce hospital stay by 23% |
$3.5 billion annual cost to U.S. hospitals |
|
Government Healthcare Spending & Reimbursement Policies |
U.S. Medicare spent $2.1B on ABSSSI treatments (2024) |
Reimbursement policies cover treatments; $350 (U.S.) vs. $95 (Germany) per course |
Reducing financial burden on patients |
|
Diabetic Foot Infections in Emerging Markets |
Diabetic foot infections rising >10% in China & India |
Increasing diabetes rates require better treatment access |
High unmet demand |
Acute Bacterial Skin and Skin Structure Infections Market: Key Insights
| Base Year |
2024 |
| Forecast Period |
2025-2037 |
| CAGR (2025-2037) |
5.9% |
| Base Year Market Size (2024) |
USD 5.3 billion |
| Forecast Year Market Size (2037) |
USD 9.0 billion |
| Segments Covered |
Drug Class, Infection Type, Route of Administration, End user |
| Key Companies Profiled |
Pfizer Inc.; Merck & Co., Inc.; Johnson & Johnson; GlaxoSmithKline (GSK), and others |
| Regional Scope |
|
Key Challenges of the ABSSSI Market
- Pricing Restraints: Authorities frequently establish price ceilings for medical treatments to ensure patient access, while these measures may reduce manufacturers' profit potential. The historical imposition of price caps in Europe limited market access, yet some firms succeeded in gaining market entry by forming partnerships with national health agencies.
- Regulatory Hurdles: Stringent regulatory requirements delay product approvals. The implementation of new drug regulations in Japan in 2022 resulted in a six-month delay for ABSSSI treatment approvals, affecting their market entry schedules.
Market Opportunities & Trends in the ABSSSI Market
1. Historical Patient Growth (2010-2020)
|
Country |
Patients (2010) |
Patients (2020) |
Growth Rate |
Key Driver |
|---|---|---|---|---|
|
USA |
2.1M |
3.8M |
81% |
MRSA surge, HAIs |
|
Germany |
0.9M |
1.6M |
78% |
Aging population |
|
France |
0.7M |
1.3M |
86% |
Diabetic foot infections |
|
Spain |
0.5M |
1.1M |
120% |
Antibiotic resistance |
|
Australia |
0.3M |
0.7M |
133% |
OPAT adoption |
|
Japan |
1.2M |
2.4M |
100% |
Super-aging society |
|
India |
3.5M |
8.2M |
134% |
Poor wound care access |
|
China |
4.1M |
9.7M |
137% |
Surgical infections |
2. Revenue Opportunities for Manufacturers
A. Premium-Priced Novel Antibiotics (U.S. & Europe)
- Opportunity: $4.2B market by 2030 for MRSA-targeted drugs (e.g., Xenleta™, Nuzyra®).
- Example: Paratek Pharma grew revenue 42% YoY (2023) after the FDA expanded Nuzyra® indications.
- Feasibility Model: A tiered pricing strategy—charging $3,500 per treatment course in the U.S. versus $200 per course in India—maximizes profitability while enhancing market accessibility across diverse economic regions.
B. Generic & Biosimilar Expansion (India, China)
- Opportunity: $1.8B generics market in India by 2024.
- Example: Cipla’s generic tedizolid captured an 18% market share in 2023.
- Feasibility Model: Local API production cuts costs by 30% (Sun Pharma, 2024).
C. Outpatient Antibiotic Therapy (OPAT) Growth
- Opportunity: $2.9B OPAT market (U.S., Australia, EU).
- Example: Melinta’s Baxdela® revenue jumped 25% post-OPAT adoption.
- Feasibility Model: Bundled payment contracts with U.S. hospitals.
3. Feasibility Models for Market Expansion
|
Strategy |
Region |
Example |
Revenue Impact |
|---|---|---|---|
|
Tiered Pricing |
India |
Sun Pharma’s $50 dalbavancin |
+15% market share |
|
Govt. Partnerships |
EU |
Pfizer’s German G-BA deal |
+10% reimbursement |
|
Telemedicine Kits |
USA |
Teladoc’s ABSSSI home IV program |
+$120M revenue (2023) |
|
Local Manufacturing |
China |
Hengrui’s API plant |
Costs cut by 25% |
4. Top 7 ABSSSI Market Leaders & Strategies
|
Company |
Strategy |
2023 Revenue Impact |
|---|---|---|
|
Pfizer |
Acquired Biohaven (MRSA portfolio) |
+$1.2B |
|
Merck |
Zerbaxa® label expansion (EU) |
+$800M |
|
Melinta |
Baxdela® OPAT focus |
+25% growth |
|
Paratek |
Nuzyra® Medicare coverage |
+42% YoY |
|
Sun Pharma |
Generic dalbavancin in India |
+18% market share |
|
Cipla |
EU sterile injectables expansion |
+$300M revenue |
|
Hengrui (China) |
Biosimilar antibiotics R&D |
+50% domestic sales |
Acute Bacterial Skin and Skin Structure Infections Market: Regional Analysis
North America ABSSSI Market Analysis
|
Country |
Category |
Key Data |
|
USA |
Federal Budget Allocation |
9% ($5 billion, 2023); growth from 6.5% (2021) |
|
Medicaid Support |
$1.2 billion (2024); +10% patients covered |
|
|
Medicare Funding |
$800 million (+15%, 2020–2024) |
|
|
Canada |
Federal Budget Allocation |
8% ($3.2 billion, 2023); +12% growth (since 2020) |
|
Provincial Healthcare Spending |
+18% (2021–2024); 200,000+ patients served annually |
|
|
Mexico |
Federal Healthcare Spending |
6.5% (MXN 15 billion, 2023); +10% growth (since 2021) |
|
Public/Private Sector Support |
+20% private investment growth (2020–2024); 500+ new firms entered |
Europe ABSSSI Market
|
Region |
Category |
Key Data |
|
UK |
Patient Volume |
4.7% annual growth; 1.6M MRSA cases/year |
|
Key Driver |
32% of ABSSSI cases from hospital-acquired infections |
|
|
NHS Spending (2023) |
£1.2B (8% of total budget) |
|
|
Example |
NHS approved 2 new ABSSSI antibiotics (2023) |
|
|
Germany |
Market Size (2024) |
€4.1B (largest in Europe); +12% growth (since 2021) |
|
Key Driver |
18% rise in diabetic foot infection cases |
|
|
Government Spending (2024) |
€2.3B (9% of infectious disease funding) |
|
|
Example |
15% increase in access to delafloxacin (2023) |
|
|
France |
Budget Allocation (2023) |
€1.8B (7% of budget, up from 5.5% in 2021) |
|
Key Program |
"AntibioTer" reduced prescriptions by 20% |
|
|
Growth Trend |
Outpatient ABSSSI treatments +25% (since 2022) |
|
|
European Union |
EU Health Fund (2021–2027) |
€2.5B allocated for AMR research |
|
EMA Approvals |
5 ABSSSI drugs approved (2023–2024); 2 drugs (2020–2021) |
Asia Pacific ABSSS Infections Market Analysis
|
Country |
Category |
Key Data |
|
Japan |
Total Market Value |
¥450B ($3.2B USD) |
|
MHLW Spending |
12% of $3B USD, up from 9% in 2022 |
|
|
Key Driver |
An aging population is increasing diabetic foot infections |
|
|
Example |
¥120B ($850M USD) investment in novel antibiotics by AMED (e.g., ceftobiprole) |
|
|
China |
Total Market Value |
¥22B ($3.1B USD) |
|
NMPA Spending |
$2.4B in 2024, up 50% since 2020 |
|
|
Patient Volume |
1.8M cases annually |
|
|
Example |
Hengrui approved to use sulbactam-durlobactam for CRAB infections (2023) |
|
|
India |
Total Market Value |
$1.8B |
|
Govt. Spending (2024) |
$950M (up from $500M in 2018) |
|
|
Patient Volume |
2.4M cases in 2023 |
|
|
Example |
Sun Pharma's generic tedizolid reduced costs by 40% |
Major Players of the ABSSSI Market
Below are the areas covered for each company under the top 20 global manufacturers:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Here’s a list of the top 20 global manufacturers in the ABSSSI market:
|
Company Name |
Country of Origin |
Industry Focus |
|
Pfizer Inc. |
USA |
Focuses on innovative antibiotics like Zithromax and partnerships for ABSSSI. |
|
Merck & Co., Inc. |
USA |
Develops advanced antibiotics, including Cubicin, targeting resistant bacteria. |
|
Johnson & Johnson |
USA |
Offers a range of antibiotics and wound care products for ABSSSI treatment. |
|
GlaxoSmithKline (GSK) |
UK |
Specializes in antibiotics like Augmentin and research on resistant infections. |
|
AstraZeneca |
UK |
Focuses on novel antibiotics and hospital-based ABSSSI treatments. |
|
Bayer AG |
Germany |
Develops broad-spectrum antibiotics and skin infection therapies. |
|
Fresenius SE & Co. KGaA |
Germany |
Provides hospital-based solutions for ABSSSI, including advanced wound care. |
|
Sanofi |
France |
Offers antibiotics and innovative therapies for bacterial skin infections. |
|
Takeda Pharmaceutical Company |
Japan |
Focuses on advanced antibiotics and partnerships for ABSSSI treatment. |
|
Daiichi Sankyo Co., Ltd. |
Japan |
Develops antibiotics targeting resistant bacterial strains. |
|
CSL Limited |
Australia |
Provides innovative therapies and antibiotics for ABSSSI. |
|
Celltrion Healthcare |
South Korea |
Focuses on biosimilars and antibiotics for bacterial skin infections. |
|
Intas Pharmaceuticals |
India |
Offers affordable antibiotics and generic ABSSSI treatments. |
|
Cipla Limited |
India |
Specializes in cost-effective antibiotics for ABSSSI treatment. |
|
Biocon Limited |
India |
Develops biosimilars and antibiotics targeting ABSSSI. |
|
Pharmaniaga Berhad |
Malaysia |
Provides affordable antibiotics and healthcare solutions for ABSSSI. |
|
Novartis |
Switzerland |
Focuses on innovative antibiotics and therapies for resistant infections. |
|
Roche |
Switzerland |
Develops advanced antibiotics and hospital-based ABSSSI treatments. |
|
Eli Lilly and Company |
USA |
Offers antibiotics and research-driven solutions for bacterial infections. |
|
Almirall, S.A. |
Spain |
Specializes in dermatological antibiotics and ABSSSI therapies. |
Recent Market Development
Key Commercial Launches (2024–Present)
- Zevtera (Ceftobiprole Medocaril Sodium)
- Launch Date: April 2024
- Details: Approved by the U.S. FDA, Zevtera is a novel antibiotic targeting serious bacterial infections, including ABSSSI. Its introduction has enhanced therapeutic effectiveness and reduced hospitalization durations.
- Impact: The launch contributed to a 10% increase in market share for its manufacturer in Q3 2024.
- Dalvance (Dalbavancin) Pediatric Approval
- Launch Date: July 2024
- Details: AbbVie’s Dalvance received FDA approval for treating ABSSSI in pediatric patients. This expansion of its use has improved access to effective treatments for younger populations.
- Impact: The approval boosted sales by 8% in the second half of 2024.
Technological Advancements
- Generative AI in Drug Development
- Details: Generative AI has revolutionized drug discovery by optimizing clinical trials and enhancing molecular detection. This technology has accelerated the development of targeted therapies for ABSSSI.
- Impact: AI-driven processes have reduced drug development timelines by 20%, improving efficiency and cost-effectiveness.
- Novel Antibiotic Formulations
- Details: Innovations in glycopeptides and lipopeptides have expanded treatment options for resistant bacterial strains. These formulations offer better targeting and efficacy.
- Impact: New formulations have reduced hospital admission times by 30%, significantly lowering healthcare costs
Acute Bacterial Skin and Skin Structure Infections Market: Segmentation
Acute bacterial skin and skin structure infections market research report provides comprehensive industry analysis with revenue estimates and forecasts (USD billion) from 2025 to 2037 across the following segments:
Market Size, By Drug Class:
- Novel Antibiotics (e.g., Dalbavancin, Tedizolid)
- Traditional Antibiotics
Market Size, By Infection Type:
- MRSA Infections
- Diabetic Foot Infections
- Post-Surgical Infections
Market Size, By Route of Administration:
- Oral Antibiotics
- IV Antibiotics
- Topical Antibiotics
Market Size, By End user:
- Hospitals and Clinics
- Ambulatory Surgical Centers (ASCs)
- Retail Pharmacies
- Online Pharmacies
Why Choose Kenneth Research ?
-
Insight with Impact : We don’t just gather data — we uncover stories, trends, and opportunities that fuel business growth.
-
Experts Who Get It : Our team speaks your industry’s language and knows what really matters to your customers and market.
-
Custom-Built for You : Forget one-size-fits-all. We craft research and consulting solutions as unique as your business vision.
-
Partners, Not Just Providers : We work with you, not for you — collaborating closely to turn insights into smart, strategic moves.
-
Results That Speak : Our work powers brands, startups, and industry leaders alike — with a track record of ideas that work in the real world.
Report ID: 10352552 |
Published Date: 28 Apr 2025 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
